- Home
- STTK vs INO Comparison
STTK vs INO Comparison
Compare STTK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | INO |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 136.6M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | STTK | INO |
|---|---|---|
| Price | $2.60 | $2.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.00 | ★ $9.00 |
| AVG Volume (30 Days) | 171.3K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,751.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.30 |
| 52 Week High | $2.71 | $4.61 |
Technical Indicators
Market Signals| Indicator | STTK | INO |
|---|---|---|
| Relative Strength Index (RSI) | 71.07 | 48.63 |
| Support Level | $1.93 | $1.86 |
| Resistance Level | $2.18 | $2.10 |
| Average True Range (ATR) | 0.18 | 0.12 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 97.78 | 76.92 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.